CellOxess

CellOxess is a biotechnology company based in Ewing, New Jersey, in the United States. It describes itself as being solely dedicated to promoting optimal health and wellness by restoring cellular redox balance. Its work sits at the intersection of bio-analytical assay development and natural prophylactic products: on one side it develops methods to detect and quantify oxidative stress, and on the other it formulates antioxidant nutraceuticals intended to mitigate it. The company's scientific premise is that many health conditions share a common underlying mechanism — oxidative stress — and that accurate measurement of redox status can yield clinically useful information. CellOxess states that it is developing bioassays that use tissue-specific markers of oxidative stress to pinpoint the onset of health deterioration, combining semi-quantitative and analytical methods to profile an individual's redox status. This profiling is positioned as a way to generate clinical insight into the risk of various health conditions and to support tailored patient treatment strategies. A distinctive emphasis of the company is reproductive health. CellOxess says its ongoing research revolves around identifying and quantifying biomarkers found in men's sperm and seminal fluid and in women's follicular fluid. The stated aims are to improve the accuracy of predicting assisted reproductive technology (ART) outcomes and to evaluate whether antioxidant treatments may be needed to support and improve reproductive health. Beyond reproduction, the company also frames redox balance as relevant to cardiovascular, metabolic and neurological health. On the product side, CellOxess develops what it calls natural prophylactic solutions — antioxidant nutraceutical formulations personalized for optimum safety and efficacy. The company says it applies principles of pharmaceutical design and delivery and pharmaceutical standards of research and development to create antioxidant formulations that have been extensively tested and proven safe and effective, with the goal of restoring normal redox balance and supporting normal cellular structure and function. It also states a commitment to substantiating all marketed products with pre-clinical or clinical evidence published in reputable journals, and to maintaining academic research collaborations with scientists worldwide. CellOxess LLC was founded by Dr. Parviz Gharagozloo, who serves as its president and chief executive officer. According to the company's own account, he has more than 25 years of experience in organic and medicinal chemistry gained in academia, technology transfer, biotech and pharmaceutical companies in the United Kingdom and the United States. Before CellOxess, he led a group of medicinal chemists at Purdue Pharma in Cranbury, New Jersey, targeting receptors, enzymes and ion channels for the discovery of novel analgesics; before that he was head of medicinal chemistry at Napp Pharmaceuticals, a pain-specializing company in Cambridge, UK, where he led multiple drug-discovery research programs and served on the board of directors. He began his professional research career in 1990 at the Medical Research Council Technology Center at Mill Hill in London. The company operates as a private entity and presents itself as a research-driven biotechnology business rather than a mass-market consumer brand. Its public communications emphasize assay development, biomarker research, pharmaceutical-grade formulation standards and evidence substantiation, alongside a nutraceutical product line aimed at consumers and, potentially, clinical partners.

CellOxess LLC is a privately held biotechnology company based in Ewing, New Jersey, in the United States. It was founded by Dr. Parviz Gharagozloo, who serves as its president and chief executive officer. The company's public materials do not state a precise founding year, but its leadership biography places its origins after Dr. Gharagozloo's pharmaceutical-industry career in the United Kingdom and the United States. Dr. Gharagozloo's background shaped the company's scientific direction. He began his professional research career in 1990 at the Medical Research Council Technology Center at Mill Hill in London, where he spent three years as a postdoctoral researcher. He then moved into industry, becoming head of medicinal chemistry at Napp Pharmaceuticals, a pain-specializing company in Cambridge, UK, where he led multiple drug-discovery research programs and served on the board of directors. In 2000 he joined Purdue Pharma in Cranbury, New Jersey, where he led a group of medicinal chemists targeting receptors, enzymes and ion channels for the discovery of novel analgesics. His stated experience spans more than 25 years in organic and medicinal chemistry across academia, technology transfer, biotech and pharmaceutical companies in the UK and the USA. Building on that medicinal-chemistry foundation, CellOxess was established around a specific scientific thesis: that oxidative stress is a common underlying mechanism across many health conditions, and that redox balance is key to systemic and reproductive health. The company's mission, as stated on its website, is to develop precise bio-analytical methods for the detection and mitigation of oxidative stress using safe and efficacious nutraceuticals. From that mission, CellOxess developed two connected lines of work. The first is bio-analytical: the identification and characterization of health 'bio-indicators'. The company says it is dedicated to developing innovative bioassays that use tissue-specific markers of oxidative stress to pinpoint the onset of health deterioration. By employing a mix of semi-quantitative and analytical methods, it profiles an individual's redox status, which it says yields critical clinical insights regarding the risk of various health conditions and facilitates tailored patient treatment strategies. A central goal is the development of assays specifically designed to enhance the clinical care pathway, with a particular emphasis on reproductive health. Its ongoing research revolves around identifying and quantifying biomarkers found in men's sperm and seminal fluid and in women's follicular fluid, aiming both to improve the accuracy of predicting assisted reproductive technology (ART) outcomes and to evaluate the potential need for antioxidant treatments. The second line of work is product development: natural prophylactic solutions in the form of antioxidant nutraceuticals personalized for optimum safety and efficacy. CellOxess states that it seeks to understand the biomolecular roles of antioxidants and their synergistic actions in maintaining cell homeostasis, which is necessary for normal tissue function. Using principles of pharmaceutical design and delivery, it focuses on creating antioxidant formulations that have been extensively tested and proven safe and effective, with the aim of restoring a normal redox balance and promoting normal cellular structure and function. The company frames this as relevant to cardiovascular, metabolic, neurological and particularly reproductive health. CellOxess also emphasizes external validation and collaboration. Its stated commitments include developing and maintaining strong academic research collaborations with pioneering scientists worldwide, and substantiating all marketed products with pre-clinical or clinical evidence published in reputable journals. The company presents itself as pioneering the future of human health through novel assessment of bio-indicators and innovation of natural solutions, and it operates as a private company rather than a publicly listed one.

• 2000

  Gharagozloo joins Purdue Pharma in Cranbury, New Jersey, leading a medicinal chemistry group targeting receptors, enzymes and ion channels for novel analgesics.

• 1990

  Founder Parviz Gharagozloo begins his professional research career at the Medical Research Council Technology Center at Mill Hill, London, UK.

• CellOxess LLC is founded by Parviz Gharagozloo, who serves as president and CEO.

• CellOxess develops bioassays using tissue-specific oxidative stress markers and antioxidant nutraceutical formulations, with a focus on reproductive health biomarkers.

Research-driven biotechnology company combining pharmaceutical-grade assay development with natural antioxidant nutraceuticals, with a particular emphasis on reproductive health.

• Oxidative stress bioassays

  Bioassays using tissue-specific markers of oxidative stress to pinpoint the onset of health deterioration, combining semi-quantitative and analytical methods to profile an individual's redox status.

• Reproductive health biomarker assays

  Research focused on identifying and quantifying biomarkers in men's sperm and seminal fluid and women's follicular fluid, to improve prediction of assisted reproductive technology (ART) outcomes and evaluate antioxidant treatment needs.

• Antioxidant nutraceuticals

  Natural prophylactic formulations personalized for optimum safety and efficacy, developed using pharmaceutical design and delivery principles to restore normal redox balance.

1. 1Pioneering the future of human health | CellOxesscelloxess.com
2. 2Products & Services | CellOxesscelloxess.com
3. 3About | CellOxesscelloxess.com
4. 4CellOxess (United States) - Wikidatawikidata.org